Cancer Evolution during Immunotherapy

M. C. Andrews; J. A. Wargo

doi:10.1016/j.cell.2017.10.027

Cancer Evolution during Immunotherapy

M. C. Andrews
, J. A. Wargo

Surgical Oncology

Research output: Contribution to journal › Short survey › peer-review

28 Scopus citations

Abstract

Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy. Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.

Original language	English (US)
Pages (from-to)	740-742
Number of pages	3
Journal	Cell
Volume	171
Issue number	4
DOIs	https://doi.org/10.1016/j.cell.2017.10.027
State	Published - Nov 2 2017

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2017.10.027

Cite this

@article{e39ebfd23d9a441186a627ec8e7c90f6,

title = "Cancer Evolution during Immunotherapy",

abstract = "Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy. Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.",

author = "Andrews, \{M. C.\} and Wargo, \{J. A.\}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = nov,

day = "2",

doi = "10.1016/j.cell.2017.10.027",

language = "English (US)",

volume = "171",

pages = "740--742",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Cancer Evolution during Immunotherapy

AU - Andrews, M. C.

AU - Wargo, J. A.

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy. Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.

AB - Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy. Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.

UR - https://www.scopus.com/pages/publications/85032661843

UR - https://www.scopus.com/pages/publications/85032661843#tab=citedBy

U2 - 10.1016/j.cell.2017.10.027

DO - 10.1016/j.cell.2017.10.027

M3 - Short survey

C2 - 29100071

AN - SCOPUS:85032661843

SN - 0092-8674

VL - 171

SP - 740

EP - 742

JO - Cell

JF - Cell

IS - 4

ER -

Cancer Evolution during Immunotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this